Cargando…

Outcomes of Patients With Metastatic Differentiated Thyroid Cancer After Excellent Response to Treatment

BACKGROUND: To evaluate the outcomes in differentiated thyroid cancer (DTC) patients who achieved excellent response to initial treatment and developed distant metastasis during follow-up. METHODS: Thyroid cancer patients registered in Chang Gung Memorial Hospital thyroid cancer database between Jan...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Chia-Jung, Lai, Kun-Yu, Lu, Yu-Ling, Wu, Ming-Hsien, Liu, Feng-Hsuan, Lin, Shu-Fu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273717/
https://www.ncbi.nlm.nih.gov/pubmed/35837311
http://dx.doi.org/10.3389/fendo.2022.923182
_version_ 1784745139431800832
author Hsu, Chia-Jung
Lai, Kun-Yu
Lu, Yu-Ling
Wu, Ming-Hsien
Liu, Feng-Hsuan
Lin, Shu-Fu
author_facet Hsu, Chia-Jung
Lai, Kun-Yu
Lu, Yu-Ling
Wu, Ming-Hsien
Liu, Feng-Hsuan
Lin, Shu-Fu
author_sort Hsu, Chia-Jung
collection PubMed
description BACKGROUND: To evaluate the outcomes in differentiated thyroid cancer (DTC) patients who achieved excellent response to initial treatment and developed distant metastasis during follow-up. METHODS: Thyroid cancer patients registered in Chang Gung Memorial Hospital thyroid cancer database between January 1979 and December 2019 were assessed. RESULTS: Among 1053 DTC patients with excellent response to initial therapy, 14 (1.3%) patients developed metastatic disease during follow-up, including 6 males and 8 females with median age of 50.2 years [interquartile range (IQR), 39.9-53.7]. Nine (64.3%) patients had papillary cancer, four (28.6%) had follicular cancer, and one (7.1%) had Hürthle cell cancer. Most patients (92.9%) had stage I disease at diagnosis. The sites of metastasis were lung (71.4%), bone (7.1%), mediastinum (7.1%) and multiple sites (14.3%). With a median follow-up of 18.3 years (IQR, 14.8-23.8), 2 patients had disease-specific mortality. The 5- and 10-year disease-specific survival after the diagnosis of distant metastasis was 92% and 74%, respectively. Multiple sites of metastasis was associated with increased risk of mortality (P = 0.022). CONCLUSIONS: A small proportion of DTC patients with an excellence response to initial therapy developed distant metastasis during follow-up. Multiple organ distant metastases conferred a worse disease-specific survival.
format Online
Article
Text
id pubmed-9273717
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92737172022-07-13 Outcomes of Patients With Metastatic Differentiated Thyroid Cancer After Excellent Response to Treatment Hsu, Chia-Jung Lai, Kun-Yu Lu, Yu-Ling Wu, Ming-Hsien Liu, Feng-Hsuan Lin, Shu-Fu Front Endocrinol (Lausanne) Endocrinology BACKGROUND: To evaluate the outcomes in differentiated thyroid cancer (DTC) patients who achieved excellent response to initial treatment and developed distant metastasis during follow-up. METHODS: Thyroid cancer patients registered in Chang Gung Memorial Hospital thyroid cancer database between January 1979 and December 2019 were assessed. RESULTS: Among 1053 DTC patients with excellent response to initial therapy, 14 (1.3%) patients developed metastatic disease during follow-up, including 6 males and 8 females with median age of 50.2 years [interquartile range (IQR), 39.9-53.7]. Nine (64.3%) patients had papillary cancer, four (28.6%) had follicular cancer, and one (7.1%) had Hürthle cell cancer. Most patients (92.9%) had stage I disease at diagnosis. The sites of metastasis were lung (71.4%), bone (7.1%), mediastinum (7.1%) and multiple sites (14.3%). With a median follow-up of 18.3 years (IQR, 14.8-23.8), 2 patients had disease-specific mortality. The 5- and 10-year disease-specific survival after the diagnosis of distant metastasis was 92% and 74%, respectively. Multiple sites of metastasis was associated with increased risk of mortality (P = 0.022). CONCLUSIONS: A small proportion of DTC patients with an excellence response to initial therapy developed distant metastasis during follow-up. Multiple organ distant metastases conferred a worse disease-specific survival. Frontiers Media S.A. 2022-06-28 /pmc/articles/PMC9273717/ /pubmed/35837311 http://dx.doi.org/10.3389/fendo.2022.923182 Text en Copyright © 2022 Hsu, Lai, Lu, Wu, Liu and Lin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Hsu, Chia-Jung
Lai, Kun-Yu
Lu, Yu-Ling
Wu, Ming-Hsien
Liu, Feng-Hsuan
Lin, Shu-Fu
Outcomes of Patients With Metastatic Differentiated Thyroid Cancer After Excellent Response to Treatment
title Outcomes of Patients With Metastatic Differentiated Thyroid Cancer After Excellent Response to Treatment
title_full Outcomes of Patients With Metastatic Differentiated Thyroid Cancer After Excellent Response to Treatment
title_fullStr Outcomes of Patients With Metastatic Differentiated Thyroid Cancer After Excellent Response to Treatment
title_full_unstemmed Outcomes of Patients With Metastatic Differentiated Thyroid Cancer After Excellent Response to Treatment
title_short Outcomes of Patients With Metastatic Differentiated Thyroid Cancer After Excellent Response to Treatment
title_sort outcomes of patients with metastatic differentiated thyroid cancer after excellent response to treatment
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273717/
https://www.ncbi.nlm.nih.gov/pubmed/35837311
http://dx.doi.org/10.3389/fendo.2022.923182
work_keys_str_mv AT hsuchiajung outcomesofpatientswithmetastaticdifferentiatedthyroidcancerafterexcellentresponsetotreatment
AT laikunyu outcomesofpatientswithmetastaticdifferentiatedthyroidcancerafterexcellentresponsetotreatment
AT luyuling outcomesofpatientswithmetastaticdifferentiatedthyroidcancerafterexcellentresponsetotreatment
AT wuminghsien outcomesofpatientswithmetastaticdifferentiatedthyroidcancerafterexcellentresponsetotreatment
AT liufenghsuan outcomesofpatientswithmetastaticdifferentiatedthyroidcancerafterexcellentresponsetotreatment
AT linshufu outcomesofpatientswithmetastaticdifferentiatedthyroidcancerafterexcellentresponsetotreatment